Literature DB >> 22292749

MicroRNAs in cancer: small molecules, big chances.

Mohammed Abba1, Giridhar Mudduluru, Heike Allgayer.   

Abstract

MicroRNAs have come to represent a significant mechanism of post transcriptional gene regulation affecting processes as varied as cellular differentiation, proliferation, metabolism, apoptosis, and cancer. As more miRNAs are unravelled and their roles dissected, it has become evident that the involvement of these molecules in cancer is much more extensive than initially thought. Several miRNA expression analyses in both haematological malignancies and solid tumors have shown that, aside significant differences in expression between tumor and normal states, distinct tumor specific miRNA signatures exist. Additionally, the ability of miRNAs to mediate both oncogenic and tumor suppressor functions further broadens their functional significance. In recent years, efforts have intensified to utilize miRNAs therapeutically, especially in the context of oncomirs. As far as the impact and the success of this approach are concerned, it is still early days, but the potential is enormous. This review focuses on the important miRNAs that have been found to impact the tumorigenic process, how far we have come in terms of utilizing these molecules for therapy and the outlook for the near future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22292749     DOI: 10.2174/187152012802650273

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  18 in total

1.  Delivery of Exogenous miR-124 to Glioblastoma Multiform Cells by Wharton's Jelly Mesenchymal Stem Cells Decreases Cell Proliferation and Migration, and Confers Chemosensitivity.

Authors:  S Sharif; M H Ghahremani; M Soleimani
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

Review 2.  Contribution of bioinformatics prediction in microRNA-based cancer therapeutics.

Authors:  Jasjit K Banwait; Dhundy R Bastola
Journal:  Adv Drug Deliv Rev       Date:  2014-11-06       Impact factor: 15.470

3.  Quantitative proteomic analysis of gene regulation by miR-34a and miR-34c.

Authors:  Olivia A Ebner; Matthias Selbach
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

4.  miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1.

Authors:  Yanhua Liu; Jing Jiang; Xinjing Wang; Fei Zhai; Xiaoxing Cheng
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

Review 5.  ApoptomiRs of Breast Cancer: Basics to Clinics.

Authors:  Shivani Sharma; Praveen K Patnaik; Stella Aronov; Ritu Kulshreshtha
Journal:  Front Genet       Date:  2016-09-29       Impact factor: 4.599

Review 6.  MicroRNA Regulation of Epithelial to Mesenchymal Transition.

Authors:  Mohammed L Abba; Nitin Patil; Jörg Hendrik Leupold; Heike Allgayer
Journal:  J Clin Med       Date:  2016-01-14       Impact factor: 4.241

7.  MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway.

Authors:  Guosheng Tan; Linwei Wu; Jinfu Tan; Bing Zhang; William Chi-shing Tai; Shiqiu Xiong; Wei Chen; Jianyong Yang; Heping Li
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

8.  MiR-186-3p attenuates tumorigenesis of cervical cancer by targeting IGF1.

Authors:  Xiurong Lu; Xiao Song; Xiaohui Hao; Xiaoyu Liu; Xianyu Zhang; Na Yuan; Huan Ma; Zhilin Zhang
Journal:  World J Surg Oncol       Date:  2021-07-12       Impact factor: 2.754

9.  Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity.

Authors:  Jessian L Munoz; Sarah A Bliss; Steven J Greco; Shakti H Ramkissoon; Keith L Ligon; Pranela Rameshwar
Journal:  Mol Ther Nucleic Acids       Date:  2013-10-01       Impact factor: 10.183

10.  MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6.

Authors:  Li Yuan; Shaolin Li; Qi Zhou; Dong Wang; Dongling Zou; Jin Shu; Yu Huang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.